Archive - MS-Selfie

Q&A 57: Is my pseudorelapse due to smouldering MS?

I am hoping that in the future, we will be able to distinguish between true relapses (new focal inflammatory activity) and pseudorelapses by measuring…

8 hrs ago •

Gavin Giovannoni

9:52

Self-agency in MS - is it realistic?

Can healthcare professionals (HCPs) expect their patients with MS to have self-agency and manage their own MS-related symptoms?

Nov 1 •

Gavin Giovannoni

October 2024

Q&A 56: Natalizumab switching: adverse events on Tyruko

Patients can experience the nocebo effect when they switch to generic or biosimilar drugs. Are these reports due to the nocebo effect?

Oct 28 •

Gavin Giovannoni

Can we continue to ignore the evidence that T-cells are fundamental to MS?

Is it not time to take off the B-cell blinkers? Do you think MS-Selfie is the appropriate platform for highlighting key research findings in MS?

Oct 27 •

Gavin Giovannoni

Q&A 55: Should I have a third course of cladribine?

How effective is a third course of cladribine (Mavenclad) in halting disease progression?

Oct 24 •

Gavin Giovannoni

7:22

Smouldering associated or SAW index and MS-CREATE a brain game

Could SAW have been detected earlier in these pwMS if cognition was being monitored using sensitive tests? Does it matter?

Oct 21 •

Gavin Giovannoni

Serious infections on anti-CD20 therapies

Most serious infections on ocrelizumab happen in people with MS with normal immunoglobulin levels

Oct 17 •

Gavin Giovannoni

Sleep, sleep, glorious sleep

Are you surprised by the insomnia survey results?

Oct 15 •

Gavin Giovannoni

Q&A 54: switching DMTs due to recurrent infections on ocrelizumab

My recommendation would be to switch. I would not recommend ponesimod or adaptive (less frequent) ocrelizumab dosing.

Oct 14 •

Gavin Giovannoni

11:55

Gabapentinoids, yet another dirty secret

Some people with MS are on ten or more concomitant medications including gabapentin or pregabalin. Are you?

Oct 8 •

Gavin Giovannoni

Q&A 53 - more on tolebrutinib and BTKIs

What does tolebrutinib teach us about the differences between progressive and relapsing biology?

Oct 4 •

Gavin Giovannoni

NHS in crisis: waiting lists, post-code prescribing and more ...

I suspect a few of these patients on the waiting will turn out to have MS, and waiting 9, 12 or 18 months for a diagnosis will come at a cost. MS waits…

Oct 3 •

Gavin Giovannoni

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts